Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBerlanga, Pablo
dc.contributor.authorPierron, Gaelle
dc.contributor.authorLacroix, Ludovic
dc.contributor.authorChicard, Mathieu
dc.contributor.authorAdam de Beaumais, Tiphaine
dc.contributor.authorMarchais, Antonin
dc.contributor.authorSoriano Fernández, Aroa
dc.contributor.authorHladun Alvaro, Raquel
dc.date.accessioned2022-09-07T11:25:43Z
dc.date.available2022-09-07T11:25:43Z
dc.date.issued2022-05-01
dc.identifier.citationBerlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, et al. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. Cancer Discov. 2022 May 1;12(5):1266–81.
dc.identifier.issn2159-8290
dc.identifier.urihttp://hdl.handle.net/11351/8044
dc.descriptionPrecision Medicine; Pediatric and Adolescent Patients; Recurrent Malignancies
dc.description.abstractMAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/ refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered “ready for routine use.” Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies—56% of them within early clinical trials—mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resulted in a 17% objective response rate, and of those patients with ready for routine use alterations, it was 38%. In patients with extracerebral tumors, 76% of actionable alterations detected in tumor tissue were also identified in circulating cell-free DNA (cfDNA).
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesCancer Discovery;12(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Recaiguda
dc.subjectMedicina personalitzada
dc.subjectPediatria
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrecision Medicine
dc.subject.meshNeoplasms
dc.titleThe European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/2159-8290.CD-21-1136
dc.subject.decsrecurrencia neoplásica local
dc.subject.decsmedicina de precisión
dc.subject.decsneoplasias
dc.relation.publishversionhttps://doi.org/10.1158/2159-8290.CD-21-1136
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Berlanga P] Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. [Pierron G] Unité de Génétique Somatique, Service de Génétique, Hospital Group, Institut Curie, Paris, France. [Lacroix L] Department of Pathology and Laboratory Medicine, Translational Research Laboratory and Biobank, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. [Chicard M] INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Research Center, PSL Research University, Institut Curie, Paris, France. [Adam de Beaumais T] Clinical Research Direction, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. [Marchais A] INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France. [Soriano Fernandez A] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Hladun-Alvaro R] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35292802
dc.identifier.wos000795663800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record